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PreviewsRemarkable in the study is that the
exceptionally comprehensive analysis
facilitated extraction of information
about interconnectivity of dysregulated
genes and identification of novel key
regulatory node genes that might be
important for aortic calcification. Thus,
the work by Theodoris et al. represents
a significant step forward in shedding
light on the mechanism of aortic valve
calcification, the epigenome and tran-
scriptome in a human disease model
of which can be altered by dose-reduc-
tion of a transcription factor, illustrating
possible pathways for therapeutic
intervention.REFERENCES
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The transmission of mitochondrial DNA (mtDNA) disease from a mother with a heteroplasmic mtDNA muta-
tion to her children is unpredictable. In a recent issue of Cell, Reddy et al. (2015) present the potential for
mitochondrial-targeted nucleases to remove mutated mtDNA through the induction of heteroplasmy shift
in oocytes and zygotes.Mitochondria are the centerpiece of
cellular metabolic machinery and contain
multiple copies of a small genome, the
mtDNA. Because an individual cell con-
tains hundreds of mitochondria, each
with its own varying genome, there is a
substantial amount of mitochondrial
genomic diversity, and this phenomenon
is referred to as mtDNA heteroplasmy.
Diseases associated with mtDNA muta-
tions are unexpectedly common and
represent a broad range of deteriorating
conditions. The estimated incidence of
mtDNA disease in adults is 1 in 5,000,
but low levels of pathogenic mutations
have been detected in 1 out of 200
births. Pathogenic mutations provoke
symptoms only when mutant mtDNA isabove a specific threshold, and every
new mtDNA mutation creates a hetero-
plasmic mixture. Thus, a shift, or change
in percentage of mutant alleles through
replicative segregation, in mtDNA hetero-
plasmy is responsible for the pathoge-
nicity of mitochondrial diseases. The
mechanism by which this segregation
occurs in either somatic or germ cells re-
mains unknown (Wai et al., 2008). Impor-
tantly, mutated copies of mtDNA in the
oocyte are transmitted to the embryo,
but transmission of mtDNA disease from
a mother with a heteroplasmic mtDNA
mutation to her children is unpredictable.
Preimplantation genetic diagnosis of em-
bryos in affected mothers can reduce,
but not eliminate, mitochondrial diseasedue to uncontrolled heteroplasmy. There-
fore, affected mothers have no real
choices for having healthy children except
to play a form of reproductive ‘‘roulette,’’
where they are left to choose between
risking the possibility of their child having
disabilities and a shortened life or termi-
nating their pregnancy.
In a recent issue ofCell, Reddy and col-
leagues address this issue by exploiting
mtDNA heteroplasmy as a therapeutic
opportunity rather than an insurmount-
able problem (Reddy et al., 2015). Also,
they take advantage of the poor capacity
of the mitochondria to repair damaged
mtDNA. To this end they use mitochon-
drial-targeted nucleases to remove
mutated mtDNA in oocytes and zygotesll 16, May 7, 2015 ª2015 Elsevier Inc. 457
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Previewsinducing specific damage in mutated
mtDNA. Their approach is an attractive
strategy for future therapy of mtDNA
disorders wherein pathogenic conditions
can be prevented without completely
removing mutant alleles by simply
dropping their levels below a specific
threshold.
As a proof of concept, the authors
first used the NZB/BALB heteroplasmic
mice, which contain two mtDNA haplo-
types, BALB and NZB, and selectively
prevented their germline transmission us-
ing either mitochondria targeted restric-
tion endonucleases or TALENs designed
to remove BALB mtDNA (mito-ApaL1
nuclease) or NZB mtDNA (NZB-TALEN).
Next they worked with two known
humanmtDNA diseases: Leber hereditary
optic neuropathy (LHON), characterized
by bilateral, painless, subacute visual
failure that develops during young adult
life, and NARP (neurogenic muscle weak-
ness, ataxia, and retinitis pigmentosa),
characterized by proximal neurogenic
muscle weakness with sensory neuropa-
thy, ataxia, and pigmentary retinopathy.
Reddy et al. designed mito-TALENs tar-
geted for the selective elimination of
human mitochondrias harboring muta-
tions of LHOND m.14459G>A and NARP
m.9176T>C in human oocytes. The use
of designed restriction nucleases and
heterodimeric zinc finger nucleases for
the induction of heteroplasmy shift has
been previously demonstrated in human
somatic cells (Bacman et al., 2013; Gam-
mage et al., 2014). In the case of mtZFNS,
Gammage et al. achieved a reduction in
mutant mtDNA haplotype load following
repopulation of wild-type mtDNA and
restored mitochondrial respiratory func-
tion by shifting to the healthy mitochon-
drial population.
Targeting genome-editing tools such as
ZFNs, TALENs, and CRISPR to the mito-
chondria has outstanding potential to
reduce pathogenic mtDNA mutations;
however, several limitations must be
overcome prior to their use in the clinic.
In this paper, Reddy and colleagues
have resolved one of the key challenges
by using mRNA injected into the oocyte458 Cell Stem Cell 16, May 7, 2015 ª2015 Elto express LHOND and NARP mito-
TALEN. Mouse oocytes were fused to fi-
broblasts and expression of mito-TALENs
removed mutant mtDNA, generating a
heteroplasmy shift. The use of RNA cir-
cumvents the disadvantages of exoge-
nous DNA administration, such as the
‘‘three-genome baby’’ issue (Callaway,
2014). In addition, RNA is easier to handle
compared to more sophisticated spindle
transfer techniques.
However, it is important to acknowl-
edge that genetic mis-targeting poses
several potential problems: many of the
potential targets require discrimination
from indistinguishable regions in non-
target mtDNA using only one base.
Additionally, achieving high efficiency
of importing endonucleases specifically
into mitochondria is critical to avoid off-
target effects in the nuclear genome,
particularly for ZFNs, which have an
intrinsic tropism for the nucleus (Bacman
et al., 2014). Moreover, reducing mtDNA
in the early embryo may be problematic,
as no mtDNA replication is believed to
occur between fertilization and post-
implantation stages (Piko´ and Taylor,
1987). The total amount of mtDNA is split
among cells during embryonic division;
thus, by day 5 of development, each em-
bryonic cell likely contains few copies
of mtDNA. Nevertheless, some data
indicate that partial/mutant mtDNA deple-
tion presumably would not impact em-
bryo viability and implantation potential.
Indeed, Tfam knockout mice, despite
fewer mitochondria in oocytes, exhibit
normal fertilization and early develop-
ment (Wai et al., 2010). Further, mitochon-
dria in mammalian oocytes have few
cristae, which suggests that they have
poor oxidative phosphorylation capacity.
Combined, these observations suggest
that the embryo is largely dependent on
energy accumulation during oocyte matu-
ration; thus, a reduction in mtDNA at early
embryonic stages should not greatly
affect the development potential.
The potential to use a heteroplasmatic
shift approach is further supported by the
observation that mitochondrial dysfunc-
tion is often associated with substantialsevier Inc.mitochondrial hyperproliferation. Conse-
quently, partial mtDNA depletion may
stimulate an increase in non-pathogenic
mtDNA copy number in early embryos.
This has been demonstrated recently
by Monnot et al. (2013), who show that
the m.3243A>G MELAS mutation pro-
duces a gradual increase in mtDNA copy
number from the germinal vesicle oocyte
to the blastocyst stage. Thus, we can
speculate that partial depletion of
mutated mtDNA will stimulate mitochon-
drial biogenesis, givingnon-targetedmito-
chondria an advantage in displacing the
mutant population.
The heteroplasmic shift approach using
mitochondrial target nucleases is prom-
ising for reducing the transmission of
pathogenic mtDNA. Future improvements
of this technology will involve the use of
purified nuclease protein or even a combi-
nation of RNA and protein at the meiosis II
oocyte stage. In order to make specific
nuclease design for each mutation afford-
able, we will require better molecular and
bioinformatics tools that will be available
in the near future.REFERENCES
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